{"version":"1.0","type":"link","title":"Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.","author_name":"Zarba M 외","author_url":"https://prs-insight.online/author/Zarba%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167161","thumbnail_width":1200,"thumbnail_height":630}